Drug Monitoring Assess Panel, Extended, Quantitative, Urine
- Laboratory
- Quest Diagnostics
- Test code
- 39992
- Specimen
- Urine
- Fasting
- Not stated
- LOINC
- 106132-4, 10975-1, 11052-8, 11075-9, 12382-8, 12602-9, 15372-6, 16114-1, 16249-5, 17395-5, 17719-6, 18322-8, 18338-4, 18355-8, 19328-4, 19346-6, 19570-1, 19611-3, 2161-8, 2756-5, 28073-5, 2965-2, 33339-3, 33507-5, 3394-4, 3415-7, 3508-9, 3637-6, 3681-4, 3725-9, 3755-6, 3774-7, 3780-4, 3831-5, 3875-2, 3887-7, 3937-0, 49753-7, 50542-0, 54247-2, 58714-7, 59589-2, 59680-9, 60677-2, 61422-2, 61425-5, 64125-8, 65807-0, 65808-8, 72768-5, 82524-0, 96059-1, 9835-0
Laboratory assay overview
A single direct to definitive panel with the ability to identify multiple specific drugs and metabolites across drug classes facilitates enhanced patient care. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.
View complete laboratory reference notes
See Laboratory Report
Quest Diagnostics test directory, test code 39992